Mutations and response to epidermal growth factor receptor inhibitors.
about
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaReceptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A ReviewThe tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients.An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.Cancer stem cells and their mechanism of chemo-radiation resistanceEndoplasmic reticulum calcium pumps and cancer cell differentiation.Physiological regulation of Akt activity and stability.Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation.Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data.PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer.Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer.Treatment of unresectable and metastatic cutaneous squamous cell carcinoma.Sulforaphane attenuates EGFR signaling in NSCLC cellsSynergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.Braf and erbB2 mutations correlate with smoking status in lung cancer patients.Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.Profiling cancer testis antigens in non-small-cell lung cancer.Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.Pathogenesis of pancreatic cancer: lessons from animal models.Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.Non-small cell lung cancer: the era of targeted therapy.c-Cbl mediates the degradation of tumorigenic nuclear β-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors.Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceBeyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis.K-Ras promotes the non-small lung cancer cells survival by cooperating with sirtuin 1 and p27 under ROS stimulation.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.
P2860
Q26784091-F3E22CAE-EAE7-4226-85ED-FA158A004A6AQ27851674-10E8BBE5-D7C2-4EA1-87A4-8BE74BF533C7Q28074119-C619D8D0-C481-41B8-82A9-4E37671D4B22Q33604936-77FDAA74-B762-4DD3-9CCE-4CFB20D58FBEQ33613086-F6B86DE5-0431-4B37-9C1F-C72672E8BB6FQ33614696-B6315E98-E1DC-4A4D-B22A-6EB63435F024Q33649613-61C40A85-3759-4931-B86E-A871E73C5F62Q33680673-96EADDD7-1B8E-4ACE-B050-ECB9323A925BQ33859710-8342F092-4142-48B9-A404-4D595D502949Q34042708-51A1F077-4710-4DA8-AD33-D89090283ABEQ34173721-7899DB4B-5C51-4B31-BC3A-E4A6D74038F2Q34436731-ECF0AC28-5119-4C92-AD57-0BA369E53C8FQ34498746-C9A24A03-E07B-49A1-9A9D-004BFAF19634Q34570685-A62A0056-FCB8-4452-9F10-817D38C4B3D6Q34581970-186D14FA-52AA-450B-83BF-5426ADBF7326Q34966603-18299C5A-DCA8-4066-B38B-1907E61CC43BQ34985562-E4B5FB74-D533-495A-BF54-DC3C5133DD29Q34991189-9929AF9B-D5D5-4A3F-998A-B299064490FBQ35583860-D186569C-8EDA-4EC1-8016-78B90D99AF9CQ35673332-6BCE1BF5-B4C6-46F9-9423-AB08EA263B69Q35691935-40B08EE6-DFD2-4530-BBD8-E183A1D2DB00Q36224108-E8A0F835-0DDC-47D7-B739-17B5E6F9933BQ36582547-64515358-2A20-47ED-A860-CE529DBB64BDQ37277266-50BC994B-5B0A-4AF9-9537-C13C9522474AQ37525082-5DF337E1-21C8-428E-B697-903F28D69880Q37588340-2E5B4510-4E0D-4A12-86DD-E467FB5E578FQ37589374-4142FE97-BE59-455A-8409-255BAAC76C3BQ37632159-061C69BF-9473-427B-8FAD-805E70458D71Q37645231-366DDFFB-FC61-4655-B45F-EB77C10D8B5AQ37687584-22AB5BC4-AB1E-48D7-B1D6-63936F32E0A1Q37698720-C23C3FE2-D76B-4172-ACAD-CE332DB30F5BQ37837732-563A6825-799F-4188-BA66-A185F204D9D7Q37899687-475C99B9-8779-4ACF-A9F2-58DD38B83D84Q38101885-F2AF8C10-56E8-4FF3-9017-B646F3A3BCB9Q38118934-52949EA8-FAEF-495D-B502-E79769BF16C9Q38222512-F1A6E5DA-B778-468F-9446-0C97B66BC9C0Q38667738-1F003745-77C3-4F03-94EC-10D7EAB36C50Q38884503-48723B8C-66BF-4A7C-8A1E-CBBD6F57685BQ38920359-F9FDA362-3BC1-4FFE-82FF-22E62B1B2EB5Q38985863-516718B5-42CD-42BA-8D72-1F250313C899
P2860
Mutations and response to epidermal growth factor receptor inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mutations and response to epidermal growth factor receptor inhibitors.
@en
Mutations and response to epidermal growth factor receptor inhibitors.
@nl
type
label
Mutations and response to epidermal growth factor receptor inhibitors.
@en
Mutations and response to epidermal growth factor receptor inhibitors.
@nl
prefLabel
Mutations and response to epidermal growth factor receptor inhibitors.
@en
Mutations and response to epidermal growth factor receptor inhibitors.
@nl
P1476
Mutations and response to epidermal growth factor receptor inhibitors.
@en
P2093
Astrid Lievre
Hélène Blons
P304
P356
10.1158/1078-0432.CCR-08-0905
P407
P577
2009-02-01T00:00:00Z